AGK2, a SIRT2 inhibitor, ameliorates D‐galactose‐induced liver fibrosis by inhibiting fibrogenic factors
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Aslı Nur Bahar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Sirtuin 2, Galactose, Rats, Sprague-Dawley, Liver Cirrhosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Arastirma Kurumu.
Abstract (Originalsprache)
In our study, we aimed to investigate the effect of SIRT2 inhibition on function, fibrosis and inflammation in liver fibrosis induced by D ‐Galactose (D‐Gal) administration. A total of 32 3‐month‐old Sprague Dawley rats were used in the study. Rats were divided into 4 groups as Control, d ‐Gal, Solvent+ d ‐Gal, d ‐Gal+AGK2+Solvent. d ‐Gal (150 mg/kg/day), AGK‐2 (10 µM/bw) as a specific SIRT2 inhibitor, 4%DMSO + PBS as a solvent was applied to the experimental groups and physiological saline was applied to the control group for 10 weeks. All applications were performed subcutaneously. Histological fibrotic changes were studied in the liver tissues by Masson's trichrome staining, hematoxylin and eosin staining and immunohistochemistry and the levels of selected factors were determined by quantitative reverse transcription‐polymerase chain reaction, western blot analysis, and immunohistochemical analysis. Biochemical parameters and Paraoxonase levels were determined in the plasma. d ‐Galactose administration increased AST, AST‐ALT Ratio, APRI, SIRT2 protein expression, IL1β, TGF β, β‐catenin, Type I collagen, Type III collagen and α‐SMA, collagen fiber density and histopathological score. ALT and lipid panels were not changed and paraxonase plasma level was shown to decrease. These effects were largely blocked by the SIRT2 inhibitor AGK2. These findings suggest that SIRT2 inhibition attenuates d ‐Gal‐induced liver injury and that this protection may be due to its antifibrotic and anti‐inflammatory activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
- Department of Physiology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
- Department of Histology and Embryology, Faculty of Medicine, Izmir Bakircay University, Izmir, Turkey.
- Cancer Research Institute, Faculty of Medicine, Ankara University, Ankara, Turkey.
- Department of Physiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Förderung
- Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
Zitieren
APA
Bahar, A. N., Keskin-Aktan, A., Akarca-Dizakar, S. Ö., Sonugür, G., & Akbulut, K. G. (2024). AGK2, a SIRT2 inhibitor, ameliorates D‐galactose‐induced liver fibrosis by inhibiting fibrogenic factors. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70000
Vancouver
Bahar AN, Keskin-Aktan A, Akarca-Dizakar SÖ, Sonugür G, Akbulut KG. AGK2, a SIRT2 inhibitor, ameliorates D‐galactose‐induced liver fibrosis by inhibiting fibrogenic factors. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.70000
BibTeX
@article{Bahar2024,
author = {Bahar, Aslı Nur and Keskin-Aktan, Arzu and Akarca-Dizakar, Saadet Özen and Sonugür, Gizem and Akbulut, Kazime Gonca},
title = {AGK2, a SIRT2 inhibitor, ameliorates D‐galactose‐induced liver fibrosis by inhibiting fibrogenic factors},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.70000}
}
EUVIMED